Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07361354 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)
A Phase 1 study of Healthy Participants and Pharmacokinetic Study, sponsored by Angitia Incorporated Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07361354 is a Phase 1 study of Healthy Participants and Pharmacokinetic Study that is actively recruiting participants, run by Angitia Incorporated Limited. The registered enrollment target is 30 participants, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07361354, a Phase 1 study of Healthy Participants and Pharmacokinetic Study, is actively recruiting participants, sponsored by Angitia Incorporated Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the effects of a single dose of AGA2118 in Japanese, Chinese, and Caucasian participants
Conditions Studied
Interventions
- DRUG AGA2118
Study Locations (1)
California
- Los Angeles EPCU - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-01-05 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07361354
The ClinicalTrials.gov registry entry for NCT07361354 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (54% lower). The listed sponsor is Angitia Incorporated Limited, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Healthy Participants appearing as the primary indexed condition, and to 1 intervention - of which AGA2118 is the first listed.
NCT07361354 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT07361354 about?
NCT07361354 is a clinical study titled "A Phase 1 Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)". This study will evaluate the effects of a single dose of AGA2118 in Japanese, Chinese, and Caucasian participants
What is the current status of trial NCT07361354?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2026-01-05. Estimated completion is 2026-11.
What conditions does trial NCT07361354 study?
This clinical trial studies the following conditions: Healthy Participants, Pharmacokinetic Study.
What interventions are being tested in trial NCT07361354?
The interventions under investigation include: AGA2118 (DRUG).
Who is sponsoring clinical trial NCT07361354?
This trial is sponsored by Angitia Incorporated Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07361354 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.